1. Home
  2. PULM vs COHN Comparison

PULM vs COHN Comparison

Compare PULM & COHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PULM
  • COHN
  • Stock Information
  • Founded
  • PULM 2003
  • COHN 1999
  • Country
  • PULM United States
  • COHN United States
  • Employees
  • PULM N/A
  • COHN N/A
  • Industry
  • PULM Biotechnology: Pharmaceutical Preparations
  • COHN Investment Bankers/Brokers/Service
  • Sector
  • PULM Health Care
  • COHN Finance
  • Exchange
  • PULM Nasdaq
  • COHN Nasdaq
  • Market Cap
  • PULM 21.0M
  • COHN 20.2M
  • IPO Year
  • PULM N/A
  • COHN N/A
  • Fundamental
  • Price
  • PULM $6.11
  • COHN $10.04
  • Analyst Decision
  • PULM
  • COHN
  • Analyst Count
  • PULM 0
  • COHN 0
  • Target Price
  • PULM N/A
  • COHN N/A
  • AVG Volume (30 Days)
  • PULM 40.5K
  • COHN 7.3K
  • Earning Date
  • PULM 11-08-2024
  • COHN 03-05-2025
  • Dividend Yield
  • PULM N/A
  • COHN 10.05%
  • EPS Growth
  • PULM N/A
  • COHN N/A
  • EPS
  • PULM N/A
  • COHN 2.35
  • Revenue
  • PULM $10,005,000.00
  • COHN $89,555,000.00
  • Revenue This Year
  • PULM N/A
  • COHN N/A
  • Revenue Next Year
  • PULM $1.00
  • COHN N/A
  • P/E Ratio
  • PULM N/A
  • COHN $4.24
  • Revenue Growth
  • PULM 47.05
  • COHN 63.18
  • 52 Week Low
  • PULM $1.55
  • COHN $6.10
  • 52 Week High
  • PULM $8.44
  • COHN $12.82
  • Technical
  • Relative Strength Index (RSI)
  • PULM 51.10
  • COHN 49.51
  • Support Level
  • PULM $5.95
  • COHN $9.30
  • Resistance Level
  • PULM $6.30
  • COHN $10.05
  • Average True Range (ATR)
  • PULM 0.43
  • COHN 0.40
  • MACD
  • PULM -0.10
  • COHN -0.03
  • Stochastic Oscillator
  • PULM 11.86
  • COHN 54.81

About PULM Pulmatrix Inc.

Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

Share on Social Networks: